OKs new generation Boston Scientific heart pacing devices
Send a link to a friend
[April 16, 2014]
U.S. health regulators have approved four Boston Scientific
Corp implantable devices for heart patients, including a next
generation of smaller defibrillators to treat abnormal heart
rhythms, the company said on Tuesday.
The Food and Drug Administration approved for sale
the Dynagen Mini and Inogen Mini ICDs and the Dynagen X4 and Inogen
X4 CRT-Ds, Boston Scientific said.
The Mini ICDs are up to 20 percent smaller by volume and up to 24
percent thinner than rival devices from other companies, Boston
Scientific said. Implantable cardioverter defibrillators treat
arrhythmias by shocking a dangerously racing heartbeat back into
"The tiny size of the Mini ICD provides a real benefit to some
patients, in particular those with a smaller frame," Dr.
Hans-Joachim Trappe from University Marien Hospital Herne, Hospital
of Ruhr-University, Bochum, Germany, said in a statement.
The CRT-Ds, or cardiac resynchronization therapy defibrillators, are
also used to protect against sudden cardiac death due to abnormal
heart rhythms in patients suffering from heart failure, in which the
heart is unable to pump blood sufficiently.
[to top of second column]
Boston Scientific shares rose to $13.45 in extended trading on
Tuesday from a New York Stock Exchange close of $13.35.
(Reporting by Bill Berkrot; editing by Peter Galloway)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.